US equities |
META $620.19 ▼-1.64% MU $928.76 ▲+2.77% NVDA $217.94 ▲+0.90% TSLA $407.46 ▲+4.04% SPCX $148.58 ▲+1.14% AAPL $347.10 ▲+0.93% AMD $560.26 ▲+5.45% MSFT $531.33 ▼-0.24%
FinancialContent

Articles published by Revive Therapeutics Ltd.

< Previous 1 2 Next >
News headline image
Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases
From Revive Therapeutics Ltd.
Via ACCESS Newswire
Tickers CSE:RVV RVVTF
News headline image
Revive Therapeutics Announces Proposed Shares for Debt Settlement
From Revive Therapeutics Ltd.
Via ACCESS Newswire
Tickers CSE:RVV RVVTF
News headline image
Revive Therapeutics Outlines Strategy to Build a Biodefence and Pandemic Preparedness Therapeutics Portfolio
From Revive Therapeutics Ltd.
Via ACCESS Newswire
Tickers CSE:RVV RVVTF
News headline image
Revive Therapeutics Reports Grant of Options
From Revive Therapeutics Ltd.
Via ACCESS Newswire
Tickers CSE:RVV RVVTF
News headline image
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
News headline image
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
News headline image
Revive Therapeutics Announces Closing of Second Tranche of Private Placement
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
News headline image
Revive Therapeutics Announces Extension of Proposed Private Placement
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
News headline image
Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
News headline image
Revive Therapeutics Announces Proposed Private Placement and Debt Settlement
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
News headline image
Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
News headline image
Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
News headline image
Revive Therapeutics Advances with Next-Generation Bucillamine Development
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
News headline image
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
News headline image
Revive Therapeutics Announces Proposed Shares for Debt Transaction
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
News headline image
Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
News headline image
Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:DMED CSE:RVV DGNMF RVVTF
News headline image
Revive Therapeutics Announces Results of Annual Shareholder Meeting
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
News headline image
Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:DMED CSE:RVV DGNMF RVVTF
News headline image
Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
News headline image
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
News headline image
Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:PHRM CSE:RVV PHRRF RVVTF
News headline image
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
News headline image
Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
News headline image
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
News headline image
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
News headline image
Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
News headline image
Revive Therapeutics Provides Update From FDA Meeting for Long COVID Diagnostic Product
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
News headline image
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
News headline image
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
< Previous 1 2 Next >